inclusion criteria: * patients admitted with sars-cov-2 (covid19) pneumonia confirmed by antigenic test or pcr age ≥ 18 yrs. * pcr ≥ 66 mg/l and ≤150 mg/l at inclusion or pandemic score at admission \> 200 with pcr 9.7-149 mg/l at inclusion. * who scale level 4, with need for oxygen therapy in ng ≥ 1 lpm to maintain saturation ≥ 94%. * onset of symptoms ≤ 10 days before the date of inclusion. * after having received verbal and written information about the study, the patient must submit the signed and dated informed consent before performing any activity related to the study.

inclusion criteria: * patients admitted with sars-cov-2 (covid19) pneumonia confirmed by antigenic test or pcr age ≥ 18 yrs. * pcr ≥ 66 mg/l and ≤150 mg/l at inclusion or pandemic score at admission \> 200 with pcr 9.7-149 mg/l at inclusion. * who scale level 4, with need for oxygen therapy in ng ≥ 1 lpm to maintain saturation ≥ 94%. * onset of symptoms ≤ 10 days before the date of inclusion. * after having received verbal and written information about the study, the patient must submit the signed and dated informed consent before performing any activity related to the study.

inclusion criteria: patients admitted with sars-cov-2 (covid19) pneumonia confirmed by antigenic test or pcr age ≥ 18 yrs. pcr ≥ 66 mg/l and ≤150 mg/l at inclusion or pandemic score at admission > 200 with pcr 9.7-149 mg/l at inclusion. who scale level 4, with need for oxygen therapy in ng ≥ 1 lpm to maintain saturation ≥ 94%. onset of symptoms ≤ 10 days before the date of inclusion. after having received verbal and written information about the study, the patient must submit the signed and dated informed consent before performing any activity related to the study.

inclusion criteria: patients admitted with sars-cov-2 (covid19) pneumonia confirmed by antigenic test or pcr age ≥ 18 yrs. pcr ≥ 66 mg/l and ≤150 mg/l at inclusion or pandemic score at admission > 200 with pcr 9.7-149 mg/l at inclusion. who scale level 4, with need for oxygen therapy in ng ≥ 1 lpm to maintain saturation ≥ 94%. onset of symptoms ≤ 10 days before the date of inclusion. after having received verbal and written information about the study, the patient must submit the signed and dated informed consent before performing any activity related to the study.